Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aerie Pharmaceuticals

15.25
0.0000
Volume:- -
Turnover:18.53M
Market Cap:753.62M
PE:-19.77
High:15.25
Open:15.25
Low:15.25
Close:15.25
52wk High:15.37
52wk Low:4.81
Shares:49.42M
Float Shares:43.75M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7712
EPS(LYR):-1.6145
ROE:-2255.01%
ROA:-4.59%
PB:-4.60
PE(LYR):-9.45

Loading ...

Company Profile

Company Name:
Aerie Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.